Pharmaceuticals in Japan industry profile is an essential resource for top-level data and analysis covering the pharmaceuticals industry.

The Internet is becoming a major source of healthcare and treatment information in Japan. In fact, Datamonitor research shows that surveyed consumers in Japan spend the most time online compared to surveyed consumers in the US and Europe. Regional and

Datamonitor`s PharmaVitae Japanese Comparator Tool builds from the PharmaVitae profiles included in the report `Japanese Pharma to 2010`. This new tool allows you to compare the 15 leading players in this market by current and forecast sales by therapy

Dominated by domestic companies in the past, the Japanese pharmaceutical market is evolving, as regulatory changes stimulate direct western competition and generic penetration, and government cost containment measures restrict the market. The Japanese

The Japanese Merger Analysis Tool models the potential outcome of a merger between any of the 15 Japanese pharma companies tracked by PharmaVitae. Users can retain or divest specific products, rationalize forecasts, analyze the resulting company by for

An analysis of key players and growth strategies evaluates the strengths and weaknesses of the top 10 Japanese pharmaceutical firms` strategic and financial positions, marketed portfolios and pipeline compounds.

The government has relied on simple P&R tools to contain rising healthcare costs and provide a reasonable level of healthcare. However, factors such as a healthier elderly population are masking healthcare system inefficiencies, boosting healthcare cos

Based on an analysis of 46 companies and 1,000+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 4.9% CAGR 200511. However, behind this industry average figure there are strategic segments of the mar